GlassScriptPhysician profile
Kishan Patel
NPI 1821655473
$2,319.98
in general payments reported to CMS, 2019-2025
17 companies · $1,927 in 2025
The $1,927 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $83.66 · 2023: $135 · 2024: $175 · 2025: $1,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,764 · Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,763.75 |
| Food and Beverage | $472.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $1,763.75 | 2025 | S-217622 |
| Amgen INC. | $83.66 | 2022 | |
| Boston Scientific Corporation | $74.05 | 2024 | Embold Fibered |
| Teva Pharmaceuticals USA, INC. | $58.50 | 2023-2025 | Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $52.40 | 2023-2025 | Farxiga, Airsupra |
| Lundbeck LLC | $41.81 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $37.26 | 2023-2024 | Rexulti |
| Bard Peripheral Vascular, INC. | $36.04 | 2025 | Porter |
| Lilly USA, LLC | $33.86 | 2025 | Zepbound, Mounjaro |
| Medicomp INC | $20.29 | 2025 | Telepatch Cardiac Monitor |
| Exact Sciences Corporation | $19.50 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $19.42 | 2023 | Veozah |
| Inspire Medical Systems, INC. | $16.48 | 2023 | Inspire |
| Acadia Pharmaceuticals INC | $16.31 | 2023 | Nuplazid |
| Pfizer INC. | $16.27 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $16.04 | 2023 | Valtoco |
| Kyowa Kirin, INC. | $14.34 | 2023 | Nourianz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kishan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.